2Class PS,Jhaveri RM,Smith LR. Comparison of potency and duration of action of nalmefene and naloxone [J]. Anesth Analg, 1994,78 (3) : 536-541.
3Osbum MD,Lowery JJ,Skorpat AG,et al. In vivo characterization of the opioid antagouist nalmefene in mice [J]. Life Sci, 2010,86 (15) : 624-630.
4Sharman HS,Patnaik R, Patnaik S, et al. Antibodies to dynorphin a (1-17) attenuate closed head injury induced blood-brain barrier disruption, brain edema formation and brain pathology in the rat [J]. Acta Neurochir Suppl, 2010,106: 301-306.
3Rosen DA, Morris JL, Rosen KR, et al. Nalmefene to prevent epidural narcotic side effects in pediatric patients: a pharmacokinetic and safety study [J]. Pharmacotherapy, 2000, 20 (7): 745-9.
4Li P, Chen X, Dai X, et al. Application of a sensitive liquid chromatographic/tandem mass spectrometric method to pharmacokinetic study of nalmefene in humans [ J ]. J Chromatogr B Analyt Technol Biomed Life Sci, 2007, 852(1-2): 479-84.
5Veng Pedersen P, Wilhelm JA, Zakszewski TB, et al. Duration of opioid antagonism by nalmefene and naloxone in the dog: an integrated pharmacokinetic/pharmaeodynamic comparison [ J ]. J Pharm Sci, 1995, 84(9): 1101-6.
6Frye RF, Matzke GR, Jallad NS, et al. The effect of age on the pharmacokineties of the opioid antagonist nalmefene [J ]. Br J Clin Pharmacol, 1996, 42(3): 301-6.
7Matzke GR, Frye RF, Alexander AC, et al. The effect of renal insufficiency and hemodialysis on the pharmacokinetics of nalmefene[J]. J Clin Pharmacol, 1996, 36(2): 144-51.
8Satya SM. Stability of revex, nalmefene hydrochloride injection, in injectable solutions [J]. J Pharm Biomed Anal, 1996, 15 (2) : 221-226.
9陈灏珠.实用内科学[M](第12版)[M].北京:人民卫生出版社,2005.348-351.
10Ota K,Kpbayahi A,Vahiro M,et al.Clinical nurses attitudes about privacy in Japan[].ClinicalNuising.2003
